Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Alaunos Therapeutics (TCRT) Debt to Equity (2016 - 2023)

Alaunos Therapeutics (TCRT) has disclosed Debt to Equity for 4 consecutive years, with $0.37 as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Debt to Equity fell 24.78% year-over-year to $0.37, compared with a TTM value of $0.37 through Mar 2023, down 24.78%, and an annual FY2022 reading of $0.43, up 4.67% over the prior year.
  • Debt to Equity was $0.37 for Q1 2023 at Alaunos Therapeutics, down from $0.43 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.71 in Q3 2022 and bottomed at $0.35 in Q3 2021.
  • Average Debt to Equity over 3 years is $0.48, with a median of $0.43 recorded in 2022.
  • The sharpest move saw Debt to Equity soared 100.32% in 2022, then fell 24.78% in 2023.
  • Year by year, Debt to Equity stood at $0.42 in 2021, then increased by 4.67% to $0.43 in 2022, then fell by 14.37% to $0.37 in 2023.
  • Business Quant data shows Debt to Equity for TCRT at $0.37 in Q1 2023, $0.43 in Q4 2022, and $0.71 in Q3 2022.